Tectonic Therapeutic Inc

1. 1

   Election of Directors (Class II nominees

   ManagementBoard: FOR

   Elect the Board’s two Class II director nominees (Timothy A. Springer, Ph.D. and Stefan Vitorovic) to hold office until the 2029 Annual Meeting of Stockholders and their successors.

2. 2

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the Audit Committee’s appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Advisory Vote on Executive Compensation (Say‑on‑Pay

   ManagementBoard: FOR

   Non‑binding advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement (the Company’s “say‑on‑pay” vote).

   More detail

   This management proposal requests a non‑binding, advisory approval of the Company’s Named Executive Officer compensation as disclosed in the proxy (the ‘say‑on‑pay’). Management is seeking stockholder endorsement to validate its executive pay philosophy, which it describes as a mix of base salary for security and cash/equity incentives to align pay with company performance and retain talent. The Company frames its program as balancing competitive base pay with long‑term equity that vests over multiple years to align executive incentives with long‑term shareholder value creation. The Board and Compensation Committee emphasize that they will consider the advisory vote results when making future compensation decisions, indicating this vote serves as feedback rather than determinative governance. The Board’s stated rationale for recommending a “FOR” vote is that the compensation components are integral to attracting and retaining qualified executives and are reasonably linked to performance objectives. The proposal is non‑binding, so even if stockholders vote against the proposal, the Company’s pay practices would not automatically change, but management has committed to review and consider stockholder feedback. In the current governance context, the advisory vote also interacts with other governance features described in the proxy (clawback policy, severance and change‑in‑control protections, equity plan design), which are relevant to stockholders assessing pay alignment and risk. Given the Company’s status and recent transaction history (Merger in 2024, equity plan resets), the advisory vote will be interpreted by investors as a signal of acceptance or concern about post‑Merger executive pay levels and structure. Overall, the proposal asks shareholders to endorse management’s disclosed pay approach, while leaving the Board discretion to respond to the vote’s outcome in future compensation decisions.

4. 4

   Other Business

   Management

   To transact any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.

   More detail

   This is a catch‑all item authorizing the meeting to consider any additional matters that may properly come before the Annual Meeting and is not a discrete, substantive transaction requiring advance approval. The proxy materials state that the Board does not know of any other matters to be brought before the meeting, and if other matters are presented the named proxy holders have discretionary authority to vote in their best judgment. For beneficial holders, brokers may be unable to vote on non‑routine matters in the absence of instructions, which means additional matters could be affected by broker non‑votes; the proxy discloses that Proposals 1 and 3 are non‑routine while Proposal 2 is routine for brokers. Because this item is open‑ended, it does not include specific text beyond the standard phrase, and no board recommendation is given; instead, the proxy clarifies that proxies returned without specific instructions will be voted according to the Board’s recommendations on known items and the proxy holders’ discretion on any other matters. From a governance perspective, the item preserves procedural flexibility to address incidental business, but provides limited information for shareholders to evaluate hypothetical future items; any significant unannounced matter presented under this item could trigger scrutiny if it affects shareholder rights or fundamental corporate structure. Practically, such catch‑all resolutions rarely result in substantive contested actions at well‑governed companies because material transactions are typically disclosed in advance; however, the proxy does grant the board‑designated proxies the authority to act if necessary. Investors should note the procedural protections described elsewhere in the proxy (advance notice bylaws and related person transaction policy) that constrain unexpected governance changes and provide channels for stockholder nominations and proposals at future meetings. Given the clarity in the proxy that the Board and management expect no other matters, this item functions primarily as a procedural placeholder rather than an invitation to substantive, unvetted actions.

Upcoming shareholder meetings at Tectonic Therapeutic Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Tectonic Therapeutic Inc 2026 annual meeting?

Tectonic Therapeutic Inc (TECX) holds its 2026 annual shareholder meeting on Monday, June 8, 2026.

What is the record date for the Tectonic Therapeutic Inc 2026 meeting?

The record date for the Tectonic Therapeutic Inc 2026 meeting is Monday, April 13, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Tectonic Therapeutic Inc's 2026 meeting?

The board is presenting 2 director nominees at the Tectonic Therapeutic Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Tectonic Therapeutic Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Tectonic Therapeutic Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.